Please login to the form below

Licensing deals

This page shows the latest Licensing deals news and features for those working in and with pharma, biotech and healthcare.

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead. ... The takeover is the latest in a string of big billion dollar-plus licensing and acquisition deals signed by Gilead since the start of 2019 under new chief executive Daniel

Latest news

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

There has been a flurry of licensing deals in the coeliac disease area in recent months, including deals between GlaxoSmithKline and Sitari and Roche/Genentech and Parvus, as drugmakers eye a
Boehringer bolsters NASH pipeline with Enleofen link-up

It’s the first licensing deal for the company and is also thought to be the largest ever agreed by a Singapore biotech, with Boehringer agreeing to pay up to 1bn ( ... a series of licensing deals as well as its in-house research.
AstraZeneca launches $1bn Chinese investment fund

generic products, over a ten-year period, and has agreed licensing deals for three early-stage cancer drugs with Chinese biotech firms.
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Has potential in cardiovascular and metabolic diseases. Pfizer has bolted on an antisense drug with potential in cardiovascular and metabolic diseases to its pipeline via a licensing deal with Ionis’ Akcea ... affiliate. The big pharma – which has
Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Lundbeck hasn’t traditionally been a particularly active player in M&A, preferring to rely mainly on its in-house R&D and smaller-scale licensing deals, but has stepped up ... the pace of deals under new CEO Deborah Dunsire (pictured below).

More from news
Approximately 2 fully matching, plus 86 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

returns. That includes an exit from areas like neurology – which predates Bourla’s appointment as CEO but was set up while he was COO – and a series of bolt-on deals ... Meanwhile, Galapagos looks set to continue adding to its pipeline through
A market-adapted agile approach to launch excellence

Furthermore, increases. in region or market-specific licensing deals for launch products have led companies to devolve to region-specific cross-functional teams for tailored launch preparation, allowing different thinking to
The changing nature of approvals – what does the future hold?

Mega-mergers are also becoming less frequent; instead, we’re seeing fewer but larger deals. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the
Deal Watch October 2018

Licensing &. research. collaboration. $550m. Novartis/. Mylan. TOBI Podhaler and TOBI solution for cystic fibrosis. ... Licensing &. collaboration. $40m. All deals are for worldwide rights unless stated otherwise:.
Pharma deals continue to slide

Deal Watch investigates. There is plenty of evidence that the number and value of biopharma M&A and licensing deals in 2016 and 2017 is declining. ... Licensing . The most common licensing deal is big pharma licensing in from biotech.

More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest appointments

Ablynx appoints Markus Ewert as chief business officer

Edwin Moses, CEO of Ablynx, said: “Markus brings extensive experience in leading business development teams and executing licensing deals and acquisitions.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...